Hematology Frontier

Honored to share insights from the 67th ASH Annual Meeting, featuring an in-depth conversation with Prof. Mikkael A. Sekeres and Prof. Huafeng Wang. The discussion explores key updates and clinical…

On December 7th, local time, the highly anticipated session on the "Updated ASH Clinical Practice Guidelines on Acute Myeloid Leukemia (AML) in Older Adults" was successfully held at the American Society of Hematology (ASH) Annual Meeting. This session was chaired by Professor Mikkael Sekeres, the lead expert of the ASH guidelines and Director of the Department of Hematology at Sylvester Comprehensive Cancer Center. To gain deeper insights into the key points of the guideline update and the emerging trends it reflects, Oncology Frontier- Hematology Frontier invited Professor Huafeng Wang from Zhejiang University School of Medicine’s First Affiliated Hospital to engage in a deep dialogue with Professor Sekeres.

From December 6–9, 2025, the 67th American Society of Hematology (ASH) Annual Meeting was held in Orlando, USA. As one of the world’s largest and most influential academic events in…

Editor’s Note: Triple-negative breast cancer (TNBC) is a heterogeneous disease that historically had limited treatment options. Driven by rapid advances in antibody–drug conjugate (ADC) technology, the therapeutic landscape has seen…

Cellular immunotherapy has achieved revolutionary breakthroughs in hematologic malignancies and brought new survival opportunities to patients with relapsed or refractory disease. Autologous CAR-T cells have shown remarkable efficacy in lymphoma,…

From December 6–9, 2025, the 67th American Society of Hematology (ASH) Annual Meeting was held in Orlando, USA. As the largest and most influential global conference in hematology, ASH annually…

From December 6–9, 2025, the 67th American Society of Hematology (ASH) Annual Meeting was held in Orlando, bringing together the latest global advances in hematologic research and clinical practice. Multiple…

From December 6–9, 2025, the 67th American Society of Hematology (ASH) Annual Meeting was held in Orlando. As the world’s most influential and comprehensive academic event in hematology, ASH annually gathers tens of thousands of experts to present breakthroughs spanning basic research to clinical innovation. This year, the team led by Professor Jia Wei of Tongji Hospital, Huazhong University of Science and Technology, had seven studies accepted—one oral presentation and six posters—covering CAR-T therapy, multi-omics analysis and immunotherapy. These studies collectively illustrate a full-spectrum innovation pipeline from mechanistic discovery to translational clinical application. Hematology Frontier summarizes the key findings below and presents Professor Wei’s commentary on their broader significance.

From December 6–9, 2025, the 67th American Society of Hematology (ASH) Annual Meeting convened in Orlando, attracting tens of thousands of hematology experts worldwide. As the most influential international conference in the field, ASH showcases cutting-edge advances and breakthrough clinical findings each year. At this year’s meeting, an innovative study led by Dr. Wei Zhang of Lu Daopei Hospital was selected for poster presentation. The study introduced a novel loop-structured CD19/CD22 dual-target CAR-T therapy designed to overcome antigen escape and relapse—two major obstacles in B-cell malignancies. This approach offers renewed therapeutic hope for patients with refractory or relapsed B-cell non-Hodgkin lymphoma (B-NHL). We invited Dr. Zhang to elaborate on this research.